How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

10,974 results for

E/M Examination Criteria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle

Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Treatment (...) of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01772615 Recruitment Status : Completed First Posted : January 21, 2013 Last Update Posted : August 13, 2013 Sponsor: Hvidovre University Hospital Information provided by (Responsible Party): Andreas

2013 Clinical Trials

102. Examining Tolerance to CNS Stimulants in ADHD

International University Investigators Layout table for investigator information Principal Investigator: William E Pelham, Ph.D. Florida International University Principal Investigator: James M Swanson, Ph.D. Florida International University More Information Go to Additional Information: Layout table for additonal information Responsible Party: Florida International University ClinicalTrials.gov Identifier: Other Study ID Numbers: MH099030 First Posted: January 20, 2014 Last Update Posted: July 9, 2018 Last (...) Examining Tolerance to CNS Stimulants in ADHD Examining Tolerance to CNS Stimulants in ADHD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Examining Tolerance to CNS Stimulants in ADHD The safety

2013 Clinical Trials

103. Abdominal signs and sinograms as dependable criteria for the selective management of stabwounds of the abdomen. (PubMed)

Abdominal signs and sinograms as dependable criteria for the selective management of stabwounds of the abdomen. 5425818 1970 08 20 2018 11 13 0003-4932 172 1 1970 Jul Annals of surgery Ann. Surg. Abdominal signs and sinograms as dependable criteria for the selective management of stabwounds of the abdomen. 61-7 Haddad G H GH Pizzi W F WF Fleischmann E P EP Moynahan J M JM eng Journal Article United States Ann Surg 0372354 0003-4932 0 Benzoates 0 Contrast Media AIM IM Abdominal Injuries (...) diagnostic imaging microbiology physiopathology therapy Benzoates Contrast Media Female Humans Laparotomy Male Physical Examination Radiography 1970 7 1 1970 7 1 0 1 1970 7 1 0 0 ppublish 5425818 PMC1397079 Ann Surg. 1967 Jan;165(1):77-82 6018301 J Trauma. 1967 Mar;7(2):307-14 6018949 Am J Surg. 1960 May;99:657-64 14445378 J Trauma. 1964 Mar;4:210-8 14151155 Am J Surg. 1966 Mar;111(3):382-7 5907005 Lancet. 1947 Nov 15;2(6481):720 18896077 Surgery. 1966 Apr;59(4):650-3 5931103 Ann Surg. 1967 Aug;166(2

Full Text available with Trip Pro

1970 Annals of Surgery

104. Post Market Study of the 3DKnee™ With E-plus Insert

for a total knee replacement and meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE). Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 300 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Prospective Multicenter Open Label Study Examining the Mid- and Long-term Safety and Efficacy of the 3DKnee™ System With Vitamin E UHMWPE Tibial Inserts (3DKnee™ With E-plus (...) Insert) Study Start Date : April 2012 Estimated Primary Completion Date : June 2020 Estimated Study Completion Date : June 2024 Resource links provided by the National Library of Medicine related topics: related topics: available for: Groups and Cohorts Go to Group/Cohort Intervention/treatment 3DKnee™ with e-plus Insert Subjects who meet the indications for use criteria for the 3DKnee™ System with vitamin E UHMWPE tibial inserts (VE) and who are candidates for a primary knee arthroplasty. Device

2012 Clinical Trials

105. Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C

Shaare Zedek Medical Center Investigators Layout table for investigator information Principal Investigator: Bernardo Melamud, Dr. Gaucher Clinic , Shaare zedek Hospital More Information Go to Additional Information: Publications of Results: Zigmond E LG, Pappo O, Zangen S, Levy Sklair M, Hemed N, Rabbani E, Itamar R, Ilan Y, Margalit M. Treatment of non-alcoholic steatohepatitis by B-glucosylceramide: A phase I/II clinical study. Hepatology 2006;44 .180A, . Other Publications: Layout table (...) Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C Examining the Immune Response in Patients With Gaucher Disease and Hepatitis C - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2011 Clinical Trials

106. Systematic review on the added value of whole genome sequencing of M. tuberculosis for detection of recent transmission and outbreaks and molecular surveillance

Systematic review on the added value of whole genome sequencing of M. tuberculosis for detection of recent transmission and outbreaks and molecular surveillance Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr (...) Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing and effect measures Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Context and rationale Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Inclusion criteria: Exclusion criteria: Example: Screening will be performed in two phases, namely initial

2015 PROSPERO

107. Evidence brief on the role of bariatric surgery in super obesity (BMI > 50 kg/m^2)

text-screening: As above, with the addition of: 7. No relevant outcome measure reported ">Prioritise the exclusion criteria Example: Two reviewers will independently extract data from each article. We first try to extract numerical data from tables, text or figures. If these are not reported, we will extract data from graphs using digital ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured (...) Evidence brief on the role of bariatric surgery in super obesity (BMI > 50 kg/m^2) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

108. Prostate cancer: diagnosis and management

people who have had a negative first prostate biopsy. Discuss with the person that: there is still a risk that prostate cancer is present and and the risk is slightly higher if any of the following risk factors are present: the biopsy showed high-grade prostatic intra-epithelial neoplasia (HGPIN) the biopsy showed atypical small acinar proliferation (ASAP) abnormal digital rectal examination. [2014] [2014] If the MRI or biopsy is negativ If the MRI or biopsy is negative e 1.2.10 For people (...) the 2019 recommendations on MRI and biopsy and how they might affect practice, see rationale and impact. Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 511.2.6 Help people decide whether to have an MRI or prostate biopsy by discussing: their prostate-specific antigen (PSA) level their digital rectal examination (DRE) findings (including an estimate of prostate

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

109. Hypertension in pregnancy: diagnosis and management

10 years body mass index (BMI) of 35 kg/m 2 or more at first visit family history of pre-eclampsia multi-fetal pregnancy. [2010, amended 2019] [2010, amended 2019] Other pharmaceutical agents Other pharmaceutical agents 1.1.4 Do not use the following to prevent hypertensive disorders during pregnancy: nitric oxide donors progesterone diuretics low molecular weight heparin. [2010] [2010] Nutritional supplements Nutritional supplements 1.1.5 Do not recommend the following supplements solely (...) with the aim of preventing hypertensive disorders during pregnancy: magnesium folic acid antioxidants (vitamins C and E) Hypertension in pregnancy: diagnosis and management (NG133) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 54fish oils or algal oils garlic. [2010] [2010] Diet Diet 1.1.6 Do not recommend salt restriction during pregnancy solely to prevent gestational hypertension or pre-eclampsia. [2010] [2010

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

110. Suspected neurological conditions: recognition and referral

the face (trigeminal neur y touching the face (trigeminal neuralgia) algia) 1.3.2 Refer adults with unilateral facial pain that is triggered by touching the affected part of the face (trigeminal neuralgia) and is refractory to treatment, in line with the NICE guideline on neuropathic pain in adults. Scalp tenderness or ja Scalp tenderness or jaw claudication suggestiv w claudication suggestive of tempor e of temporal arteritis al arteritis 1.3.3 For adults with scalp tenderness or jaw claudication (...) guideline on stroke and transient ischaemic attack in over 16s. Rapidly progressiv Rapidly progressive unsteady gait (gait ataxia) e unsteady gait (gait ataxia) 1.4.2 Refer urgently adults with rapidly (within days to weeks) progressive unsteady gait (gait ataxia) for neurological assessment. Gr Gradually progressiv adually progressive unsteady gait (gait ataxia) e unsteady gait (gait ataxia) 1.4.3 Refer adults with gradually progressive unsteady gait (gait ataxia) for neurological assessment and: take

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

111. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z)

Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01215851 Recruitment Status : Completed First Posted : October 7, 2010 Results First Posted : April 1, 2016 Last Update Posted : February 28

2010 Clinical Trials

112. Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma Dar Daratumumab with bortezomib and atumumab with bortezomib and de dexamethasone for pre xamethasone for previously treated viously treated multiple m multiple my yeloma eloma T echnology appraisal guidance Published: 10 April 2019 nice.org.uk/guidance/ta573 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) received at least one prior therapy' . Dosage in Dosage in the the mark marketing eting authorisation authorisation Daratumumab 16 mg/kg body weight is administered by intravenous infusion every week for weeks 1 to 9, every 3 weeks for weeks 10 to 24 and every 4 weeks from week 25 onwards. Bortezomib is administered by subcutaneous injection at a dose of 1.3 mg/m 2 twice weekly on days 1, 4, 8 and 11 for 8×21-day cycles. Dexamethasone is administered orally at a dose of 80 mg weekly. Price Price

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

113. Age-related macular degeneration

techniques with their family members or carers (as appropriate). Monitoring for late AMD (wet activ Monitoring for late AMD (wet active e) ) 1.7.8 Offer people with late AMD (wet active) ongoing monitoring with OCT for both eyes. 1.7.9 Offer fundus examination or colour photography if OCT appearances are stable, but: there is a decline in visual acuity or or the person reports a decline in visual function. 1.7.10 Consider FFA to identify unrecognised neovascularisation if OCT appearances are stable (...) (AREDS 2001) examined the effect of antioxidant supplementation on AMD progression using the AREDS formation, which included beta carotene, vitamin E, vitamin C and zinc. Although the study showed some beneficial effects of the combined antioxidant supplementation in a subgroup of participants, the effects of each of the formula components on AMD progression were unclear. Additionally, 1 of the ingredients (beta carotene) in the AREDS 2001 formulation is associated with a possible risk of lung cancer

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

114. Chronic heart failure in adults: diagnosis and management

services if needed. [2018] [2018] Care after an acute e Care after an acute ev vent ent For recommendations on the diagnosis and management of acute heart failure see NICE's guideline on acute heart failure. 1.1.5 People with heart failure should generally be discharged from hospital only when their clinical condition is stable and the management plan is optimised. Timing of discharge should take into account the wishes of the person and their family or carer, and the level of care and support that can (...) if appropriate, and all health and social care professionals involved in their care. [2018] [2018] 1.2 Diagnosing heart failure Symptoms, signs and in Symptoms, signs and inv vestigations estigations 1.2.1 T ake a careful and detailed history, and perform a clinical examination and tests to confirm the presence of heart failure. [2010] [2010] 1.2.2 Measure N-terminal pro-B-type natriuretic peptide (NT-proBNP) in people with suspected heart failure. [2018] [2018] Chronic heart failure in adults: diagnosis

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

115. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

Chronic obstructive pulmonary disease in over 16s: diagnosis and management Chronic obstructiv Chronic obstructive pulmonary disease in e pulmonary disease in o ov ver 16s: diagnosis and management er 16s: diagnosis and management NICE guideline Published: 5 December 2018 nice.org.uk/guidance/ng115 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) is purely arbitrary response to long-term therapy is not predicted by acute reversibility testing. [2004] [2004] 1.1.19 Untreated COPD and asthma are frequently distinguishable on the basis of history (and examination) in people presenting for the first time. Whenever possible, use features from the history and examination (such as those listed in table 3) to differentiate COPD from asthma. For more information on diagnosing asthma, see the NICE guideline on asthma. [2004, amended 2018] [2004, amended

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

116. Physical examination

, and mammograms or prostate exams depending on gender. Pre-employment examinations [ ] Pre-employment examinations are screening tests which judge the suitability of a worker for hire based on the results of their physical examination. [ ] This is also called pre-employment medical clearance . Many employers believe that by only hiring workers whose physical examination results pass certain exclusionary criteria, their employees collectively will have fewer absences due to sickness, fewer workplace injuries (...) ; 25(1): 55-57. . ^ Mahmud, Norashikin; Schonstein, Eva; Schaafsma, Frederieke; Lehtola, Marika M; Fassier, Jean-Baptiste; Reneman, Michiel F; Verbeek, Jos H; Mahmud, Norashikin (2010). "Pre-employment examinations for preventing occupational injury and disease in workers". Cochrane Database of Systematic Reviews (12): CD008881. : . . ^ (February 2014), , : an initiative of the , American College of Occupational and Environmental Medicine , retrieved 24 February 2014 , which cites Talmage, J

2012 Wikipedia

117. Children and young people exposed prenatally to alcohol

for the assessment and diagnosis of children and young people affected by PAE. It includes evidence-based recommendations on measurement of alcohol consumption in pregnancy and consensus-based recommendations on: y identification of children at risk of FASD y criteria for diagnosis and use of FASD as a descriptor y medical assessment y physical examination y sentinel features y neurodevelopmental assessment y the multidisciplinary assessment team y special considerations in the neurodevelopmental assessment y (...) The need for guidance 1 1.2 Remit of the document 3 1.3 Definitions and terminology 3 1.4 Origin of this guidance 8 1.5 Statement of intent 9 2 Identification of children at risk of FASD 10 2.1 Maternal alcohol history 10 3 Identification and assessment of children and young people affected by prenatal alcohol exposure 15 3.1 Diagnostic criteria 15 3.2 Medical assessment 17 3.3 Sentinel facial features 18 3.4 Neurodevelopmental assessment 19 3.5 Special considerations in the assessment of infants

2019 SIGN

118. Lumacaftor/ivacaftor (cystic fibrosis) - Addendum to Commission A18-08

Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Addendum A18-39 Version 1.0 Lumacaftor/ivacaftor – Addendum to Commission A18-08 10 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - IQWiG employees involved in the addendum: ? Natalia Wolfram ? Lars Beckmann ? Volker Vervölgyi Keywords: lumacaftor, ivacaftor (...) . Physiotherapy d No physiotherapy at baseline 10 (9.7) 16 (15.8) Physiotherapy at baseline 93 (90.3) c 85 (84.2) c Physiotherapy at week 24 89 (86.4) c 84 (83.2) c Initiation of physiotherapy between baseline and week 24 2 (1.9) c, e 4 (4.0) c Dietary measures Not reported Not reported f a: Number of randomized patients. Values that are based on other patient numbers are marked in the corresponding line if the deviation is relevant. b: Systemic antibiotics and drugs for mycobacteria, including all with any

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

119. Dupilumab (atopic dermatitis) - Benefit assessment according to §35a Social Code Book (SGB) V

2017 Internal Commission No.: A17-63 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de Internet: www.iqwig.de Extract of dossier assessment A17-63 Version 1.0 Dupilumab (atopic dermatitis) 27 February 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - ii - Medical and scientific advice: ? Enno Schmidt, Clinic for Dermatology, University (...) Treatment duration: 52 weeks Observation: outcome- specific, follow-up: 12 weeks d 162 study centres in Australia, North America, Europe and Asia 10/2014–10/2016 e First data cut-off: 27 April 2016 f Second data cut-off: 16 December 2016 g Primary: EASI 75 h , IGA Secondary: morbidity, health-related quality of life, side effects a: Primary outcomes include information without consideration of the relevance for this benefit assessment. Secondary outcomes exclusively include information on the relevant

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

120. British guideline on the management of asthma

is made. 9, 72 In adults, absence of smoking and young age of onset are typically included in algorithms designed to distinguish asthma from COPD. 12, 14, 15, 71, 72 3.3.1 Initial structured clinical assessment The predictive value of individual symptoms or signs is poor (see Table 1), and a structured clinical assessment including all information available from the history, examination and historical records should be undertaken. The clinical features that influence the probability that episodic (...) nature of the episodic symptoms. Wheeze confirmed by a healthcare professional on auscultation (see section 3.2.1) 22 It is important to distinguish wheezing from other respiratory noises, such as stridor or rattly breathing. Repeatedly normal examination of chest when symptomatic reduces the probability of asthma. Evidence of diurnal variability 18, 19, 22, 32, 73 Symptoms which are worse at night or in the early morning. Atopic history (see section 3.2.4) 17, 22, 62, 74, 76, 77 Personal history

2019 SIGN

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>